
Philip Hampton, the British drugs giant’s chairman, is reportedly considering the move after talks with major shareholders. Such a shake-up was called for by fund manager Neil Woodford last year.
Philip Hampton, the British drugs giant’s chairman, is reportedly considering the move after talks with major shareholders. Such a shake-up was called for by fund manager Neil Woodford last year.